Max Robotics — Global Service Robot Directory + US Certification

About

Marshall Bern is a leading figure in computational biology and glycomics, whose work bridges the gap between high-throughput automation and the molecular complexity of disease. His research focuses on mass spectrometry-based proteomics and glycomics, where he has made pivotal contributions to the analysis of biotherapeutics and cancer biomarkers. Bern’s most cited work, a 2015 study on glycan motif profiling, identified elevations of sialyl-Lewis X in pancreatic cancers that are negative for the standard sialyl-Lewis A biomarker (CA19-9), offering a critical alternative for the ~25% of patients missed by current diagnostics. This paper, with 45 citations, highlights his impact on precision oncology. More recently, Bern spearheaded the “Lab of the Future” project (2023, 24 citations), designing a fully automated, multi-instrument system for high-throughput mass spectrometry analysis of biotherapeutics. This integrated platform—combining robotics, liquid handling, and LC-MS—represents a paradigm shift in biopharmaceutical characterization, dramatically accelerating drug development. Bern’s work is notable for its practical, systems-level approach, transforming complex analytical workflows into scalable, reproducible processes. His achievements underscore a career dedicated to making advanced molecular analysis both faster and more accessible, with direct implications for cancer diagnostics and therapeutic quality control.